Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$213.9MCash, Jun 2026
24moCash Runway (est.)
+8%Share Count, 1 Year
Follow ANAB by emailGet an email when ANAB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ANAB, unsubscribe in one click. Privacy
📣 What ANAB Says Is Next
in 2028 · “Data expected in 2028 Vanda Imsidolimab Financial Collaboration”
Company press release, May 12, 2026 · SEC filing
Q4 2026 · “Data expected in Q4 2026 o JADE – pivotal Phase 3 – dostarlimab monotherapy versus placebo in locally advanced unresected head and neck squamous cell carcinoma (PD-L1 CPS≥1) post chemoradiation”
Company press release, May 12, 2026 · SEC filing
in 2028 · “Data expected in 2028 o AZUR-4 – Phase 2 – dostarlimab plus chemotherapy versus standard of care (chemotherapy) in untreated stage III MMRp/MSS resectable colon cancer”
Company press release, May 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
ANAB reported $213.9M in cash and short-term investments (as of Jun 30, 2026) and used about $26.5M/quarter in operations, an estimated runway of 24.2 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANAB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.